CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2026)
CRISPR Therapeutics AG (CRSP) reported Return on Capital Employed of 27.4% for Q1 2026, down 464.0% on a YoY basis from 7.53% in Q1 2025, and up 13.17% sequentially from 31.55% in Q4 2025.
CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 11 years of Return on Capital Employed data on file, last reported at 27.4% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 464.0% year-over-year to 27.4%; the trailing twelve-month figure through Mar 2026 stood at 27.4% (down 464.0% YoY), and the FY2025 full-year result was 31.58%, down 986.0% from the prior year.
- Return on Capital Employed improved to 27.4% in Q1 2026, from 31.55% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.17% in Q1 2022 to a low of 31.55% in Q4 2025.
- A 5-year average of 21.2% and a median of 22.76% in 2025 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 3401 bps in 2022, while the deepest fall reached 4548 bps in 2022.
- Tracing CRSP's Return on Capital Employed over 5 years: stood at 30.92% in 2022, then soared by 65 bps to 10.86% in 2023, then tumbled by 99 bps to 21.59% in 2024, then tumbled by 46 bps to 31.55% in 2025, then gained by 13 bps to 27.4% in 2026.
- Business Quant data shows CRSP's Return on Capital Employed at 27.4% in Q1 2026, 31.55% in Q4 2025, and 28.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | -27.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.40% |
| Dec 31, 2025 | -31.55% |
| Sep 30, 2025 | -28.46% |
| Jun 30, 2025 | -27.71% |
| Mar 31, 2025 | -22.76% |
| Dec 31, 2024 | -21.59% |
| Sep 30, 2024 | -15.05% |
| Jun 30, 2024 | -15.68% |
| Mar 31, 2024 | -13.48% |
| Dec 31, 2023 | -10.86% |
| Sep 30, 2023 | -20.86% |
| Jun 30, 2023 | -22.69% |
| Mar 31, 2023 | -26.79% |
| Dec 31, 2022 | -30.92% |
| Sep 30, 2022 | -30.45% |
| Jun 30, 2022 | -26.25% |
| Mar 31, 2022 | 12.17% |
| Dec 31, 2021 | 14.01% |
| Sep 30, 2021 | 14.88% |
| Jun 30, 2021 | 19.23% |